Lenalidomide Qilu (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4 E3 ubiquitin ligase complex, changing its activity. This triggers the degradation of specific transcription factors, leading to anti‑angiogenic, immunomodulatory, and anti‑proliferative actions that suppress malignant cell growth and modify the immune response.

The dose is individualized by the prescribing clinician based on the specific indication, the patient’s renal function, prior therapies, and overall health status. No fixed regimen is provided here; the prescriber will calculate the appropriate amount and schedule for each patient.

Lenalidomide is classified as teratogenic and is contraindicated in pregnancy. Women of child‑bearing potential must use effective contraception during treatment and for a defined period after the last dose. Safety during breastfeeding has not been established, so breastfeeding is generally discouraged.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Both lenalidomide and thalidomide belong to the same immunomodulatory class, but lenalidomide is more potent, has a more favorable safety profile, and exhibits stronger anti‑angiogenic and anti‑myeloma activity. Thalidomide is associated with higher rates of peripheral neuropathy, whereas lenalidomide’s main concerns are hematologic toxicities.

Store Lenalidomide Qilu at ambient temperature, preferably below 25 °C (77 °F). Keep the tablets in the original container, protect them from moisture and direct sunlight, and avoid storing them in bathrooms or other humid environments.

Lenalidomide Qilu is taken orally as a tablet, usually once daily. It can be swallowed with or without food, but patients should follow the specific instructions provided by their healthcare professional regarding timing and any required dose adjustments.

The most serious risks include severe neutropenia, which can lead to life‑threatening infections; venous thromboembolism, which may cause deep‑vein thrombosis or pulmonary embolism; and the potential for second primary malignancies. Patients should be monitored closely for signs of infection, clotting, or new cancer development.

Lenalidomide Qilu should not be used by individuals who are pregnant, nursing, or have known hypersensitivity to the drug or its excipients. It is also contraindicated in patients with uncontrolled severe infections or those who cannot adhere to required contraceptive measures.